Related Experiment Videos
The current status of gene therapy
1Department of Head and Neck Surgery, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Seminars in Oncology
|August 22, 2000
Summary
Gene therapy using adenoviral p53 shows safety and activity in recurrent head and neck squamous cell carcinoma. Further studies are evaluating its role alongside surgery and DNA-damaging agents.
Area of Science:
- Oncology
- Gene Therapy
- Head and Neck Cancer Research
Background:
- Locoregionally recurrent head and neck squamous cell carcinoma presents a challenge for treatment.
- The p53 protein is crucial for cell cycle regulation and apoptosis, making it a target for cancer therapy.
Purpose of the Study:
- To evaluate the safety and efficacy of direct gene transfer of wild-type p53 into head and neck tumors.
- To explore the potential of adenoviral p53 as a therapeutic agent for recurrent head and neck squamous cell carcinoma.
Main Methods:
- Direct intratumoral injection of an adenoviral vector carrying wild-type p53 into primary or regional tumors.
- Observation of safety, tolerability, and anti-cancer activity.
Main Results:
- Adenoviral p53 gene transfer was found to be safe and well-tolerated in patients.
- Demonstrated observable anti-cancer activity in treated patients.
Conclusions:
- Adenoviral p53 is a safe and potentially active therapeutic strategy for head and neck squamous cell carcinoma.
- Ongoing randomized trials are investigating adenoviral p53 as an adjuvant to surgery and in combination with chemotherapy.